Notícias e Atividades da Tonix Pharmaceuticals
Presença
Sede: Estados Unidos
Tonix Pharmaceuticals é uma empresa listada sob o símbolo TNXP (US).
Executivos
Veja o organograma con seus 31 executivos principais
Biografias mais buscadas da Tonix Pharmaceuticals
- Seth Lederman, Co-Founder, Chairman and Chief Executive Officer
- Carolyn Taylor, Director
- Adeoye Olukotun, Director
Recentes movimentos de executivos em Tonix Pharmaceuticals
- Irina Ishak, ingressou na Companhia como General Counsel (Notícia publicada em 10 de dezembro de 2025).
- Ganesh Kamath, ingressou na Companhia como Head, Market Access (Notícia publicada em 1 de outubro de 2025).
Criar um alerta
para seguir os movimentos de executivos da Tonix Pharmaceuticals.
Farmacêutica
Tonix Pharmaceuticals possui 1.913 concorrentes concorrentes Sanofi (França), Eli Lilly (Estados Unidos) e Moderna (Estados Unidos).
Popular M&A news in Farmacêutica
- Contraline acaba de anunciar uma arrecadação de fundos de 93 milhões de dólares. (publicado em 3 de junho de 2026).
- Hims & Hers adquiriu Eucalyptus (publicado em 2 de junho de 2026).
- Apotex preencheu seu dossiê de IPO. Seu símbolo de ação será TSX. (publicado em 2 de junho de 2026).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Tonix Pharmaceuticals
- Tonix Pharmaceuticals Announces Publication of Phase 1 Clinical Data of TNX-1500, an Fc-Modified anti-CD40L (CD154) Monoclonal Antibody, in the Peer-Reviewed Journal of Clinical Immunology
- Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis of Opioid Use in Patients with Fibromyalgia at the 2026 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
- Tonix Pharmaceuticals Presented Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at The Professional Society for Health Economics and Outcomes Research (ISPOR) 2026 Annual Meeting
- Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights
- Tonix Pharmaceuticals to Participate in Two Investor Conferences in May
- Tonix Pharmaceuticals to Present Retrospective U.S. Real-World Claims Analysis Characterizing Patients with Fibromyalgia at ISPOR 2026
- Tonix Pharmaceuticals Secures Commercial Payer Coverage for TONMYA®, Providing Access for ~35 Million U.S. Patients
- Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Plans for an Adaptive Phase 2 Field Study of TNX-4800 (anti-Borrelia OspA monoclonal antibody) for the Prevention of Lyme Disease at the 4th Annual Ticks and Tickborne Diseases Symposium at
- Tonix Pharmaceuticals Presents Updates on Preclinical Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2026
- Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development
- View more press releases Close
Redes sociais sobre Tonix Pharmaceuticals
- Tonix Pharmaceuticals na Wikipedia, Google News e Yahoo Finance
- Tonix Pharmaceuticals na LinkedIn, X (Twitter) e YouTube
